外科理论与实践››2022,Vol. 27››Issue (06): 506-510.doi:10.16139/j.1007-9610.2022.06.05
王征, 包慈航, 蒋国梁(
)
收稿日期:2022-10-08出版日期:2022-11-25发布日期:2023-01-30通讯作者:蒋国梁，E-mail:
基金资助:
WANG Zheng, BAO Cihang, JIANG Guoliang()
Received:2022-10-08Online:2022-11-25Published:2023-01-30中图分类号:
王征, 包慈航, 蒋国梁. 质子重离子放射治疗在腹膜后肉瘤治疗中的价值[J]. 外科理论与实践, 2022, 27(06): 506-510.
WANG Zheng, BAO Cihang, JIANG Guoliang. Value of proton and heavy ion radiotherapy in treatment of retroperitoneal sarcoma[J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 506-510.
图1
无法切除RPS碳离子放疗的剂量分布图及剂量体积直方图 剂量方案为碳离子RBE剂量72 Gy/18次。A：剂量分布图（轴面）；B：剂量分布图（矢状面）；C：剂量体积直方图；D：剂量分布图（冠状面）。
| [1] | Nussbaum DP, Rushing CN, Lane WO, et al. Preoperative or postoperative radiotherapyversussurgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database[J]. Lancet Oncol, 2016, 17(7):966-975. doi:S1470-2045(16)30050-Xpmid:27210906 |
| [2] | Haas RLM, Bonvalot S, Miceli R, et al. Radiotherapy for retroperitoneal liposarcoma: a report from the Transatlantic Retroperitoneal Sarcoma Working Group[J]. Cancer, 2019, 125(8):1290-1300. doi:10.1002/cncr.31927pmid:30602058 |
| [3] | Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgeryversussurgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2020, 21(10):1366-1377. doi:S1470-2045(20)30446-0pmid:32941794 |
| [4] | Callegaro D, Raut CP, Ajayi T, et al. Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: EORTC-62092 trial (STRASS)versusoff-trial (STREXIT) results[J]. Ann Surg, 2022.[2022-10-08]. https://europepmc.org/article/MED/35833413. |
| [5] | Joung RHS, Wayne JD. Contemporary multimodal management of primary retroperitoneal sarcomas[J]. Adv Oncol, 2022, 2(1):63-69. |
| [6] | Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution[J]. Ann Surg, 1998, 228(3):355-365. doi:10.1097/00000658-199809000-00008pmid:9742918 |
| [7] | Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2021, 32(11):1348-1365. doi:10.1016/j.annonc.2021.07.006pmid:34303806 |
| [8] | Allignet B, Sunyach MP, Geets X, et al. Is there a place for definitive radiotherapy in the treatment of unresectable soft-tissue sarcoma? A systematic review[J]. Acta Oncol, 2022, 61(6):720-729. doi:10.1080/0284186X.2022.2066983URL |
| [9] | Salerno KE, Baldini EH. Role of radiation therapy in retroperitoneal sarcoma[J]. J Natl Compr Canc Netw, 2022, 20(7):845-849. doi:10.6004/jnccn.2022.7035URL |
| [10] | Dinges S, Budach V, Budach W, et al. Local recurrences of soft tissue sarcomas in adults: a retrospective analysis of prognostic factors in 102 cases after surgery and radiation therapy[J]. Eur J Cancer, 1994, 30A(11):1636-1642. pmid:7833136 |
| [11] | Kepka L, DeLaney TF, Suit HD, et al. Results of radiation therapy for unresected soft-tissue sarcomas[J]. Int J Radiat Oncol Biol Phys, 2005, 63(3):852-859. doi:10.1016/j.ijrobp.2005.03.004URL |
| [12] | DeLaney TF, Haas RL. Innovative radiotherapy of sarcoma: proton beam radiation[J]. Eur J Cancer, 2016, 62:112-123. doi:10.1016/j.ejca.2016.04.015pmid:27258968 |
| [13] | von Mehren M, Kane JM, Agulnik M, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(7):815-833. doi:10.6004/jnccn.2022.0035URL |
| [14] | Swanson EL, Indelicato DJ, Louis D, et al. Comparison of three-dimensional(3D) conformal proton radiotherapy (RT), 3D conformal photon RT, and intensity-modulated RT for retroperitoneal and intra-abdominal sarcomas[J]. Int J Radiat Oncol Biol Phys, 2012, 83(5):1549-1557. doi:10.1016/j.ijrobp.2011.10.014URL |
| [15] | Chung C, Trofimov A, Adams J, et al. Comparison of 3D conformal proton therapy, intensity-modulated proton therapy, and intensity-modulated photon therapy for retroperitoneal sarcoma[J]. Sarcoma, 2022, 2022:5540615. |
| [16] | Schneider RA, Vitolo V, Albertini F, et al. Small bowel toxicity after high dose spot scanning-based proton beam therapy for paraspinal/retroperitoneal neoplasms[J]. Strahlenther Onkol, 2013, 189(12):1020-1025. doi:10.1007/s00066-013-0432-0pmid:24052010 |
| [17] | Yoon SS, Chen YL, Kirsch DG, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas[J]. Ann Surg Oncol, 2010, 17(6):1515-1529. doi:10.1245/s10434-010-0935-1pmid:20151216 |
| [18] | DeLaney TF, Chen YL, Baldini EH, et al. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas[J]. Adv Radiat Oncol, 2017, 2(1):85-93. doi:10.1016/j.adro.2016.12.003pmid:28740917 |
| [19] | Minohara S, Fukuda S, Kanematsu N, et al. Recent innovations in carbon-ion radiotherapy[J]. J Radiat Res, 2010, 51(4):385-392. pmid:20679740 |
| [20] | Kamada T, Tsujii H, Blakely EA, et al. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience[J]. Lancet Oncol, 2015, 16(2):e93-e100. doi:10.1016/S1470-2045(14)70412-7URL |
| [21] | Durante M, Yamada S, Ando K, et al. X-raysvs. carbo-nion tumor therapy: cytogenetic damage in lymphocytes[J]. Int J Radiat Oncol Biol Phys, 2000, 47(3):793-798. doi:10.1016/S0360-3016(00)00455-7URL |
| [22] | Spina CS, Tsuruoka C, Mao W, et al. Differential immune modulation with carbon-ionversusphoton therapy[J]. Int J Radiat Oncol Biol Phys, 2021, 109(3):813-818. doi:10.1016/j.ijrobp.2020.09.053URL |
| [23] | Ming X, Wang W, Shahnazi K, et al. Dosimetric compa-rison between carbon, proton and photon radiation for renal retroperitoneal soft tissue sarcoma recurrence or metastasis after radical nephrectomy[J]. Int J Radiat Biol, 2022, 98(2):183-190. doi:10.1080/09553002.2022.2009144URL |
| [24] | Seidensaal K, Kieser M, Hommertgen A, et al. Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase Ⅱpilot trial[J]. Trials, 2021, 22(1):134. doi:10.1186/s13063-021-05069-zpmid:33579340 |
| [25] | Serizawa I, Kagei K, Kamada T, et al. Carbon ion radiotherapy for unresectable retroperitoneal sarcomas[J]. Int J Radiat Oncol Biol Phys, 2009, 75(4):1105-1110. doi:10.1016/j.ijrobp.2008.12.019URL |
| [26] | Imai R, Kamada T, Araki N, et al. Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma[J]. Cancer Med, 2018, 7(9):4308-4314. doi:10.1002/cam4.1679URL |
| [1] | 刘文帅, 陆维祺, 周宇红.腹膜后肉瘤诊疗规范、难点和发展方向——CSCO指南解读[J]. 外科理论与实践, 2022, 27(06): 483-489. |
| [2] | 陈骏, 罗成华.腹膜后肿瘤外科发展的历史、现状与前景展望[J]. 外科理论与实践, 2022, 27(06): 490-494. |
| [3] | 李成鹏, 郝纯毅.积极推动我国腹膜后肉瘤临床研究开展的思考[J]. 外科理论与实践, 2022, 27(06): 495-499. |
| [4] | 丁玉芹, 石洪成, 季正标.影像学检查在腹膜后肿瘤诊治中的应用及相关专家共识解读[J]. 外科理论与实践, 2022, 27(06): 511-516. |
| [5] | 杨传鑫, 王坚.运用精准外科理念提高腹膜后肿瘤外科治疗的规范性与安全性[J]. 外科理论与实践, 2022, 27(06): 517-520. |
| [6] | 谢富安, 任彦韬, 李文岗.腹膜后脂肪肉瘤研究现状和困境[J]. 外科理论与实践, 2022, 27(06): 521-525. |
| [7] | 邱法波, 周斌, 曲腾飞.腹膜后肿瘤外科的规范及手术质量控制[J]. 外科理论与实践, 2022, 27(06): 526-529. |
| [8] | 潘向欧, 张莉, 侯佳舟, 杜世锁, 曾昭冲, 王斌梁.切除困难或不可切除原发性腹膜后软组织肉瘤术前转化放射治疗的研究[J]. 外科理论与实践, 2022, 27(06): 530-533. |
| [9] | 庄奥博, 童汉兴, 张勇, 陆维祺, 周宇红, 闾晨涛.老年原发性腹膜后软组织肉瘤病人手术治疗安全性分析的回顾性队列研究[J]. 外科理论与实践, 2022, 27(06): 534-539. |
| [10] | 何燕燕, 李凤珠.膀胱原发性上皮样血管肉瘤一例报道及文献复习[J]. 诊断学理论与实践, 2022, 21(06): 719-725. |
| [11] | 袁兆琪, 顾钏, 朱朱, 罗旭松, 孙笛, 杨军.萎缩型隆突性皮肤纤维肉瘤的诊疗进展[J]. 组织工程与重建外科杂志, 2020, 16(2): 172-174. |
| [12] | 张明华, 王荟, 翁香琴, 房振, 韩志宏, 吴丽莉.腹水细胞学诊断髓系肉瘤1例报告附文献复习[J]. 诊断学理论与实践, 2020, 19(1): 88-91. |
| [13] | 曲仪庆, 张梦宇, 李慧慧,.胸膜血管肉瘤的诊治[J]. 内科理论与实践, 2020, 15(01): 11-15. |
| [14] | 周晓博，杨军，罗旭松.隆突性皮肤纤维肉瘤的治疗进展[J]. 组织工程与重建外科杂志, 2018, 14(5): 291-294. |
| [15] | 唐文, 任刚, 蔡嵘, 贺文广, 倪婧, 陈健.成人原发性横纹肌肉瘤的临床、病理及影像学特征分析[J]. 诊断学理论与实践, 2017, 16(03): 301-305. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
